Trial Profile
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Jun 2023
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 26 Jun 2014 New trial record